Research programme: adoptive cell therapeutics - Immatics

Drug Profile

Research programme: adoptive cell therapeutics - Immatics

Alternative Names: IMA 101; IMA 102; IMA 201; IMA 202; IMA 203; IMA 300; IMA 301

Latest Information Update: 25 Aug 2016

Price : $50

At a glance

  • Originator Immatics US
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 18 Aug 2016 Immatics and the University of Texas M.D. Anderson Cancer Center plan a phase I/II trial in Solid tumours (Second-line therapy or greater) in USA (NCT02876510)
  • 30 Sep 2015 Preclinical trials in Cancer in USA (unspecified route) before September 2015
  • 26 Aug 2015 Immatics and The University of Texas MD Anderson cancer centre announced the launch of Immatics US to develop adoptive cell-based therapeutics for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top